Fyn inhibition rescues established memory and synapse loss in Alzheimer mice

Therapeutic Molecules and Endogenous Ligands Regulate the Interaction between Brain Cellular Prion Protein (PrPC) and Metabotropic Glutamate Receptor 5 (mGluR5)

(2014) Laura T. Haas et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Altered Synaptic Dynamics during Normal Brain Aging

(2013) R. Mostany et al.   JOURNAL OF NEUROSCIENCE

Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease

(2013) Jean-Charles Lambert et al.   NATURE GENETICS

Anatomical Plasticity of Adult Brain Is Titrated by Nogo Receptor 1

(2013) Feras V. Akbik et al.   NEURON

Metabotropic Glutamate Receptor 5 Is a Coreceptor for Alzheimer Aβ Oligomer Bound to Cellular Prion Protein

(2013) Ji Won Um et al.   NEURON

2012 Alzheimer’s disease facts and figures

(2012)   Alzheimers & Dementia

Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma

(2012) Tara C. Gangadhar et al.   INVESTIGATIONAL NEW DRUGS

The Complex PrPc-Fyn Couples Human Oligomeric A  with Pathological Tau Changes in Alzheimer's Disease

(2012) M. Larson et al.   JOURNAL OF NEUROSCIENCE

A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline

(2012) Thorlakur Jonsson et al.   NATURE

Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons

(2012) Ji Won Um et al.   NATURE NEUROSCIENCE

Variant of TREM2 Associated with the Risk of Alzheimer's Disease

(2012) Thorlakur Jonsson et al.   NEW ENGLAND JOURNAL OF MEDICINE

TREM2 Variants in Alzheimer's Disease

(2012) Rita Guerreiro et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast Cancer

(2011) Ayca Gucalp et al.   Clinical Breast Cancer

A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium

(2011) Helen J. Mackay et al.   INVESTIGATIONAL NEW DRUGS

Amyloid-β42 Interacts Mainly with Insoluble Prion Protein in the Alzheimer Brain

(2011) Wen-Quan Zou et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Alzheimer's Disease Brain-Derived Amyloid- -Mediated Inhibition of LTP In Vivo Is Prevented by Immunotargeting Cellular Prion Protein

(2011) A. E. Barry et al.   JOURNAL OF NEUROSCIENCE

Amyloid- /Fyn-Induced Synaptic, Network, and Cognitive Impairments Depend on Tau Levels in Multiple Mouse Models of Alzheimer's Disease

(2011) E. D. Roberson et al.   JOURNAL OF NEUROSCIENCE

Alzheimer's Disease: The Challenge of the Second Century

(2011) D. M. Holtzman et al.   Science Translational Medicine

Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites

(2011) Darragh B. Freir et al.   Nature Communications

Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models

(2010) Lars M. Ittner et al.   CELL

Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors

(2010) J. Baselga et al.   CLINICAL CANCER RESEARCH

A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer

(2010) Daniel J. Renouf et al.   INVESTIGATIONAL NEW DRUGS

Memory Impairment in Transgenic Alzheimer Mice Requires Cellular Prion Protein

(2010) D. A. Gimbel et al.   JOURNAL OF NEUROSCIENCE

Postsynaptic Clustering and Activation of Pyk2 by PSD-95

(2010) J. A. Bartos et al.   JOURNAL OF NEUROSCIENCE

T cell receptor activation leads to two distinct phases of Pyk2 activation and actin cytoskeletal rearrangement in human T cells

(2010) Michaela Collins et al.   MOLECULAR IMMUNOLOGY

Tyrosine phosphorylation of tau accompanies disease progression in transgenic mouse models of tauopathy

(2010) K. Bhaskar et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

(2009) Leslie M. Shaw et al.   ANNALS OF NEUROLOGY

The T cell receptor-mediated phosphorylation of Pyk2 tyrosines 402 and 580 occurs via a distinct mechanism than other receptor systems

(2009) Michaela Collins et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

(2009) Clifford R Jack et al.   LANCET NEUROLOGY

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

(2009) Tim P. Green et al.   Molecular Oncology

Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers

(2009) Juha Laurén et al.   NATURE

Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

(2008) Ganesh M Shankar et al.   NATURE MEDICINE